Evaluation and Mechanistic Investigation of Antitumor Compounds from Dioscorea nipponica Makino subsp. rosthornii Through Spectrum-Effect Relationship Analysis - Top-Institutions - MDSpire

Evaluation and Mechanistic Investigation of Antitumor Compounds from Dioscorea nipponica Makino subsp. rosthornii Through Spectrum-Effect Relationship Analysis

  • By

  • Mengjia Liang

  • Moyu Shen

  • Yuxuan Wang

  • Pengxin Fan

  • Yuguang Zheng

  • Haiyang Wang

  • Jingcun Sun

  • Songsong Jing

  • April 29, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Cancer Pharmacology
    • Natural Product Drug Discovery

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Cancer Pharmacology
    • Translational Medicine

  • #3

    Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Shanghai Institute of Materia Medica, Chinese Academy of Sciences

    Shanghai, China

    Key Differentiators

    • Pharmacognosy
    • Natural Product Chemistry
    • Cancer Pharmacology

  • #4

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Oncology
    • Pharmacology
    • Molecular Medicine

Original Source(s)

Evaluation and Mechanistic Investigation of Antitumor Compounds from Dioscorea nipponica Makino subsp. rosthornii Through Spectrum-Effect Relationship Analysis

  • by Mengjia Liang, Moyu Shen, Yuxuan Wang, Pengxin Fan, Yuguang Zheng, Haiyang Wang, Jingcun Sun, Songsong Jing

  • April 29, 2026

Related Content

Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report

FOXA2 in cancer: from fundamental biology to clinical translation

Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC